enow.com Web Search

  1. Ads

    related to: examples of competitive enzyme inhibitors for diabetes mellitus medications

Search results

  1. Results from the WOW.Com Content Network
  2. SGLT2 inhibitor - Wikipedia

    en.wikipedia.org/wiki/SGLT2_inhibitor

    Dapagliflozin is an example of an SGLT-2 inhibitor, it is a competitive, highly selective inhibitor of SGLT. It acts via selective and potent inhibition of SGLT-2, and its activity is based on each patient's underlying blood sugar control and kidney function. The results are decreased kidney reabsorption of glucose, glucosuria effect increases ...

  3. Competitive inhibition - Wikipedia

    en.wikipedia.org/wiki/Competitive_inhibition

    Adding a competitive inhibitor to an enzymatic reaction increases the K m of the reaction, but the V max remains the same. Sulfa drugs also act as competitive inhibitors. For example, sulfanilamide competitively binds to the enzyme in the dihydropteroate synthase (DHPS) active site by mimicking the substrate para-aminobenzoic acid (PABA). [15]

  4. Alpha-glucosidase inhibitor - Wikipedia

    en.wikipedia.org/wiki/Alpha-glucosidase_inhibitor

    Alpha-glucosidase inhibitors (AGIs) are oral anti-diabetic drugs used for diabetes mellitus type 2 that work by preventing the digestion of carbohydrates (such as starch and table sugar). They are found in raw plants/herbs such as cinnamon and bacteria (containing the inhibitor acarbose ).

  5. Discovery and development of dipeptidyl peptidase-4 inhibitors

    en.wikipedia.org/wiki/Discovery_and_development...

    Dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors) are enzyme inhibitors that inhibit the enzyme dipeptidyl peptidase-4 (DPP-4). They are used in the treatment of type 2 diabetes mellitus. Inhibition of the DPP-4 enzyme prolongs and enhances the activity of incretins that play an important role in insulin secretion and blood glucose control ...

  6. Discovery and development of gliflozins - Wikipedia

    en.wikipedia.org/wiki/Discovery_and_development...

    For an example, the SGLT inhibitors are not associated with gastrointestinal adverse events and the bioavailability is much greater. [4] [12] [13] Inhibition of SGLT-2 results as better control of glucose level, lower insulin, lower blood pressure and uric acid levels and augments calorie wasting. Some data supports the hypothesis that SGLT-2 ...

  7. CYP2C9 - Wikipedia

    en.wikipedia.org/wiki/CYP2C9

    Most inhibitors of CYP2C9 are competitive inhibitors. Noncompetitive inhibitors of CYP2C9 include nifedipine, [39] [40] phenethyl isothiocyanate, [41] medroxyprogesterone acetate [42] and 6-hydroxyflavone. It was indicated that the noncompetitive binding site of 6-hydroxyflavone is the reported allosteric binding site of the CYP2C9 enzyme. [43]

  8. Dipeptidyl peptidase-4 inhibitor - Wikipedia

    en.wikipedia.org/wiki/Dipeptidyl_peptidase-4...

    DPP-4 inhibitors and GLP-1. Inhibitors of dipeptidyl peptidase 4 (DPP-4 inhibitors or gliptins) are a class of oral hypoglycemics that block the enzyme dipeptidyl peptidase-4 (DPP-4). They can be used to treat diabetes mellitus type 2. The first agent of the class – sitagliptin – was approved by the FDA in 2006. [1]

  9. Discovery and development of phosphodiesterase 5 inhibitors

    en.wikipedia.org/wiki/Discovery_and_development...

    PDE5 inhibitors have been shown to have various macrovascular, microvascular and metabolic benefits in diabetes mellitus, [3] and in a large study of men with type 2 diabetes mellitus the agents were found to significantly reduce patients' risk of death from any cause. [19]

  1. Ads

    related to: examples of competitive enzyme inhibitors for diabetes mellitus medications
  1. Related searches examples of competitive enzyme inhibitors for diabetes mellitus medications

    alpha glucosidase inhibitorsdipeptidyl inhibitors